Pharma major Ranbaxy Laboratories has launched its generic version of cholesterol lowering drug Atorvastatin in Italy, Sweden and Netherlands having received approval from local regulatory authorities.
'In accordance with its settlement agreement with Pfizer, Ranbaxy has introduced the product ahead of the applicable patent expiries. Pfizer's patent expires on May 8, 2012 and in the Netherlands and Sweden on May 6, 2012,' the company owned by Japan's Daiichi Sankyo said on Tuesday.
In Italy and Netherlands, Ranbaxy will promote the drug directly to retail pharmacies and wholesalers. In Sweden, the drug will be offered through the official pricing and reimbursement scheme covering generic medicines, to retail pharmacies, Ranbaxy said.
The company had launched Atorvastatin, a copy of Pfizer's Lipitor, in the US on November 30 and in Australia last month.
....more info
'In accordance with its settlement agreement with Pfizer, Ranbaxy has introduced the product ahead of the applicable patent expiries. Pfizer's patent expires on May 8, 2012 and in the Netherlands and Sweden on May 6, 2012,' the company owned by Japan's Daiichi Sankyo said on Tuesday.
In Italy and Netherlands, Ranbaxy will promote the drug directly to retail pharmacies and wholesalers. In Sweden, the drug will be offered through the official pricing and reimbursement scheme covering generic medicines, to retail pharmacies, Ranbaxy said.
The company had launched Atorvastatin, a copy of Pfizer's Lipitor, in the US on November 30 and in Australia last month.
....more info